Document Type
Review Article
Abstract
Background and objective
Neuromyelitis Optica Spectrum disorder (NMOSD) mostly affects the spinal cord and optic nerves. This manuscript aims to explore the treatment potential of tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor and regulates inflammatory cytokines implicated in the pathophysiology of NMOSD. Methods
A thorough search of the pertinent literature was done for this research utilising electronic databases, specifically PubMed, Cochrane Library, and Embase, which contained studies published from 2016 to 2024.
Results Clinical studies show that tocilizumab improves clinical outcomes and lowers recurrence rates in people with NMOSD, especially those who don't respond to traditional treatments. The medication's clinical utility is demonstrated by its capacity to lower MRI lesion activity, enhance Expanded Disability Status Scale (EDSS) ratings, and decrease annualised recurrence rates (ARR).
Conclusion
Tocilizumab is a major step forward in the treatment of NMOSD, although further research may be required to ascertain its long-term safety and the most effective approach to utilise it for NMO spectrum illnesses.
Recommended Citation
Mansoor, Salman; Mairajuddin, Samar Iltaf; and Gul, Saqib
(2024)
"Tocilizumab in The Management of Neuromyelitis Optica Spectrum Disorder: A Narrative Review Of Literature and Critical Appraisal,"
Pakistan Journal of Neurological Sciences (PJNS): Vol. 19:
Iss.
3, Article 6.
Available at:
https://ecommons.aku.edu/pjns/vol19/iss3/6
